Business Context and Reporting Period
Company: ILLUMINA, INC. (ILMN)
Filing Type: Form 10-Q
Reporting Period: Quarter ended March 30, 2025 (Q1 2025)
Business Overview: Illumina provides sequencing- and array-based solutions for genetic and genomic analysis. Following the June 2024 spin-off of GRAIL, the company now operates as a single reportable segment, "Core Illumina."
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $1,041 million | $1,076 million |
| Gross Profit | $683 million | $667 million |
| Gross Margin | 65.6% | 62.0% |
| Operating Income | $164 million | $(111) million |
| Net Income | $131 million | $(126) million |
| Diluted EPS | $0.82 | $(0.79) |
| Operating Cash Flow | $240 million | $77 million |
| Cash & Equivalents | $1,113 million | $1,108 million |
| Total Debt (Carrying Value) | $1,990 million | $1,989 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3% year-over-year. This was driven by the absence of GRAIL revenue following the Q2 2024 spin-off and a decrease in Core Illumina service revenue due to lower strategic partnership revenue.
- Profitability Turnaround: The company returned to profitability with $131 million in net income, compared to a $126 million net loss in Q1 2024. Operating income improved by $275 million, primarily due to a $259 million reduction in operating expenses.
- Expense Reduction: Operating expenses dropped 33% to $519 million. This decrease was largely attributable to the removal of GRAIL operating expenses ($205 million), a $27 million favorable adjustment to the GRAIL contingent consideration liability, and reduced acquisition-related legal costs.
- Restructuring: The company incurred $31 million in restructuring charges in Q1 2025, primarily for employee separation costs, as part of a new $100 million cost reduction initiative.
Guidance, Outlook, and Risks
- Tariff Impact: New tariffs enacted in April 2025 are estimated to cost the company approximately $85 million. Management aims to partially mitigate this in 2025 and fully mitigate it by 2026 through supply chain optimization and pricing actions.
- China Regulatory Risk: In February 2025, Chinese authorities added Illumina to the "List of Unreliable Entities." In March 2025, the company was prohibited from exporting sequencing instruments into China. This poses a material risk to revenue, as the Greater China region generated $308 million in revenue in 2024.
- Cost Reduction: Management implemented an incremental $100 million cost reduction program in Q1 2025 to offset revenue declines and uncertainty regarding U.S. government funding for the National Institutes of Health (NIH).
- Legal Proceedings: The SEC concluded its investigation into GRAIL in May 2025 with no enforcement action. However, multiple shareholder derivative lawsuits regarding the GRAIL acquisition remain pending in Delaware courts.
- Capital Allocation: The company repurchased $201 million of common stock in Q1 2025. Approximately $1.2 billion remains available under the current $1.5 billion repurchase authorization.
Investor Verification Checklist
- China Exposure: Verify the specific financial impact of the export ban on sequencing instruments in China and the duration of the "Unreliable Entities" listing.
- Tariff Mitigation: Assess the feasibility of the company's plan to mitigate the estimated $85 million tariff cost through pricing and supply chain changes.
- GRAIL Contingent Liability: Monitor the fair value of the GRAIL contingent consideration liability ($61 million), which is sensitive to GRAIL's future revenue forecasts and market capitalization.
- Legal Outcomes: Track the status of pending shareholder derivative lawsuits and the potential for additional litigation costs or settlements.
- NIH Funding: Evaluate the potential impact of U.S. government funding reductions for the NIH on customer demand for research instruments.